Clinical Trial

A Study to Evaluate AI-09 In Participants With Glabellar Lines

Name: A Study to Evaluate AI-09 In Participants With Glabellar Lines — clinical trial record (NCT07321834)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Record status

This record was last updated January 7, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Summary

Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.

Trial Details

NCT Number	NCT07321834
Lead Sponsor	Eirion Therapeutics Inc.
Conditions	Glabellar Lines
Enrollment	68 participants
Start Date	2025-12-03
Primary Completion	2026-02 (estimated)
Study Completion	2026-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-07